Survival Rates for Mesothelioma
5-year relative survival rates for malignant pleural mesothelioma
An advanced peritoneal mesothelioma therapy called hyperthermic intraperitoneal chemotherapy (HIPEC) has significantly improved survival rates for this cancer. The procedure combines cytoreductive surgery and heated chemotherapy. Not everyone qualifies for this aggressive procedure, but more than half who do live at least five years. This compares to a median survival of less than 12 months for patients with pleural tumors. In select studies, heated chemotherapy has boosted peritoneal survival to between 40 and 92 months. A 2015 meta-study published in Translational Oncology analyzed 20 years of data, collected from 1992 to 2012. The five-year survival rate for peritoneal mesothelioma patients was more than five-times higher than the rate for pleural patients.